Mercury Laboratories Limited (BOM:538964)

India flag India · Delayed Price · Currency is INR
849.05
-44.35 (-4.96%)
At close: May 8, 2025
-3.19%
Market Cap 1.05B
Revenue (ttm) 718.09M
Net Income (ttm) 39.45M
Shares Out 1.20M
EPS (ttm) 32.88
PE Ratio 26.70
Forward PE n/a
Dividend 3.50 (0.40%)
Ex-Dividend Date Sep 20, 2024
Volume 135
Average Volume 228
Open 890.00
Previous Close 893.40
Day's Range 849.00 - 904.80
52-Week Range 736.00 - 1,190.00
Beta 0.38
RSI 49.98
Earnings Date May 27, 2025

About Mercury Laboratories

Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-aller... [Read more]

Industry Pharmaceutical Preparations
Founded 1962
Employees 482
Stock Exchange Bombay Stock Exchange
Ticker Symbol 538964
Full Company Profile

Financial Performance

In 2023, Mercury Laboratories's revenue was 755.59 million, an increase of 0.30% compared to the previous year's 753.34 million. Earnings were 56.54 million, an increase of 1.35%.

Financial Statements

News

There is no news available yet.